search
Back to results

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Primary Purpose

Metastatic Melanoma, Unresectable Melanoma

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
IO102-IO103
Pembrolizumab
Sponsored by
IO Biotech
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Metastatic Melanoma focused on measuring Metastatic melanoma, Unresectable melanoma, Immunotherapy, Progression free survival, IO102-IO103, Pembrolizumab

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Histologically or cytologically confirmed stage III (unresectable) or stage IV melanoma, as per American Joint Committee on Cancer 8th edition guidelines not amenable to local therapy

  2. Patients are treatment naive, that is, no previous systemic anticancer therapy for unresectable or metastatic melanoma. For clarification, the following patients are eligible:

    1. Patients with proto-oncogene B-Raf (BRAFV600) mutation-positive melanoma are eligible if treatment naive and without rapidly progressive disease as per investigator assessment.
    2. Patients who have received previous adjuvant and/or neoadjuvant therapy with targeted therapy or immune therapy are eligible if administered the last dose at least 6 months before inclusion in this trial (randomization), and if relapse did not occur during active treatment or within 6 months of treatment discontinuation.
  3. At least 1 measurable lesion (not a cutaneous lesion) according to response evaluation criteria for solid tumors (RECIST v1.1) and confirmed by IRC.
  4. Provision of archival (obtained within 3 months), or newly acquired biopsy tissue not previously irradiated, and blood at screening for biomarker assessments. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue.

Exclusion Criteria:

  1. Patients with known or suspected central nervous system (CNS) metastases or with the CNS as the only site of active disease are excluded with the following exception:

    • Patients with controlled (stable) brain metastases will be allowed to enroll (subject to baseline magnetic resonance imaging (MRI) confirmation). Controlled (stable) brain metastases are defined as those with no radiographic progression for at least 4 weeks after radiation and/or surgical treatment at the time of signed informed consent. Patients must have been off steroids for at least 2 weeks before signed informed consent and have no new or progressive neurological signs and symptoms.

  2. Patient has received previous radiotherapy within 2 weeks of start of trial treatment (visit 2). Patients must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
  3. Patients with BRAFV600-positive disease who are experiencing rapidly progressing disease and/or have received standard first-line therapy with BRAF and/or MEK inhibitor for unresectable or metastatic disease.

Other protocol defined inclusion/exclusion criteria may apply.

Sites / Locations

  • Providence Saint John's Health Center
  • Mid Florida Hematology and Oncology CenterRecruiting
  • Orlando Health Cancer InstituteRecruiting
  • University of Kentucky Markey Cancer Center
  • Roswell Park Cancer InstituteRecruiting
  • VCU Massey Cancer CenterRecruiting
  • Border Medical Oncology Research UnitRecruiting
  • Westmead HospitalRecruiting
  • Southern Medical Day Care CentreRecruiting
  • Cairns HospitalRecruiting
  • Flinders Medical CentreRecruiting
  • The Queen Elizabeth Hospital
  • Sunshine Coast University HospitalRecruiting
  • Peter MacCallum Cancer Centre PMCC - East MelbourneRecruiting
  • Universitair Ziekenhuis Gent UZ GentRecruiting
  • AZ Sint-Jan Brugge - Oostende AV - Campus Sint-JanRecruiting
  • CHIRECRecruiting
  • AZ NikolaasRecruiting
  • FNHK Klinika onkologie a radioterapieRecruiting
  • Fakultni Nemocnice OlomoucRecruiting
  • FN OstravaRecruiting
  • FNKV Department of DermatologyRecruiting
  • Aalborg University HospitalRecruiting
  • Aarhus University HospitalRecruiting
  • Herlev og Gentofte HospitalRecruiting
  • Odense University HospitalRecruiting
  • Centre Hospitalier Universitaire de Besançon Jean MinjozRecruiting
  • Centre Hospitalier Universitaire de Bordeaux Hospital Saint AndreRecruiting
  • Hopital AmbroiseRecruiting
  • Centre Georges Francois LeclercRecruiting
  • Chu Grenoble - Hopital Albert MichallonRecruiting
  • Centre Hospitalier Universitaire de LilleRecruiting
  • Hôpital de La TimoneRecruiting
  • CHU de Nice Hpital de lArchet 2Recruiting
  • Centre Hospitalier Lyon SudRecruiting
  • Centre Eugene MarquisRecruiting
  • Institut de Cancérologie de L'OuestRecruiting
  • Centre Hospitalier de Valence (CHV)Recruiting
  • Gustave RoussyRecruiting
  • Universitatsklinikum Augsburg Medizincampus SuedRecruiting
  • Charite Universitaetsmedizin BerlinRecruiting
  • St. Josef Hospital - Ruhr-Universitt BochumRecruiting
  • University Hospital ErlangenRecruiting
  • Universitaetsklinikum EssenRecruiting
  • University Hospital Frankfurt Theodor-Stern-KaiRecruiting
  • Elbe Klinikum BuxtehudeRecruiting
  • Nationales Centrum fr Tumorerkrankungen NCTRecruiting
  • SLK-Kliniken Heilbronn GmbHRecruiting
  • Universitaetsklinikum Schleswig-HolsteinRecruiting
  • Department of Dermatology University of MainzRecruiting
  • Universitatsmedizin Mannheim DermatologieRecruiting
  • Mühlenkreiskliniken AöR, University Hospital Ruhr University Bochum Campus MindenRecruiting
  • LMU MuenchenRecruiting
  • Hospital TubingenRecruiting
  • Universittsklinikum WuerzburgRecruiting
  • Orszagos Onkologiai IntezetRecruiting
  • Bor, -Nemikortani es Onkodermatologiai KlinikaRecruiting
  • Hetenyi G Korhaz, Onkologiai KozpontRecruiting
  • Mater Public Hospital
  • Emek Medical CenterRecruiting
  • Ben-Gurion University of the Negev - Soroka University Medical Center - Soroka Clinical Research CenterRecruiting
  • Hadassah University HospitalRecruiting
  • Rabin Medical CenterRecruiting
  • Tel Aviv Sourasky Medical CenterRecruiting
  • The Chaim Sheba Medical Center - The Ella Lemelbaum Institute for Immuno-OncologyRecruiting
  • Clinica Oncologica, AOU Riuniti anconaRecruiting
  • Centro di Riferimento OncologicoRecruiting
  • Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico BariRecruiting
  • IRCCS Ospedale San RaffaeleRecruiting
  • IRCCS Ospedale Policlinico San MartinoRecruiting
  • Istituto Romagnolo per lo Studio dei Tumori " DINO AMADORI"Recruiting
  • Fondazione IRCCS Istituto Nazionale dei TumoriRecruiting
  • Istituto Nazionale Tumori IRCCS Fondazione PascaleRecruiting
  • Veneto Oncology InstituteRecruiting
  • Ospedale S. Maria della MisericordiaRecruiting
  • Idi-IrccsRecruiting
  • Azienda Ospedaliera Universitaria Senese Policlinico Le ScotteRecruiting
  • The Netherlands Cancer InstituteRecruiting
  • AMC Amsterdam, locatie VUMCRecruiting
  • LUMCRecruiting
  • UMC MaastrichtRecruiting
  • Erasmus MCRecruiting
  • University Medical Center UtrechtRecruiting
  • Maria Sklodowska-Curie National Research Institute of OncologyRecruiting
  • Szpital Kliniczny im. Heliodora Święcickiego UM w PoznaniuRecruiting
  • Cape Town Oncology Trials (Pty) Ltd.Recruiting
  • Mary Potter Oncology Centre GroenkloofRecruiting
  • Hospital Universitario Virgen MacarenaRecruiting
  • CH Universitario de A Coruña (CHUAC)Recruiting
  • Hospital Clinic i ProvincialRecruiting
  • Instituto Oncologico Dr. Rosell IOR - Hospital Universitari Quiron DexeusRecruiting
  • Hospital Universitari Germans Trias i Pujol HUGTP, ICO-BadalonaRecruiting
  • Hospital Vall d'hebronRecruiting
  • Hospital General Universitario Gregorio MarañonRecruiting
  • Clinica Universidad de NavarraRecruiting
  • Hospital Universitario Ramon y CajalRecruiting
  • Hospital Universitario HM SanchinarroRecruiting
  • Hospital Regional Universitario de MalagaRecruiting
  • Hospital Universitario Central de Asturias (HUCA)Recruiting
  • Clinica Universidad de NavarraRecruiting
  • Hospital General Universitario de ValenciaRecruiting
  • Hospital Universitari i Politecnic La FeRecruiting
  • Miguel Servet University HospitalRecruiting
  • Adana City Education and Research Hospital
  • Gulhane School of MedicineRecruiting
  • Memorial Ankara HospitalRecruiting
  • Akdeniz University Medical FacultyRecruiting
  • Ege university Faculty of Medicine, T. Aktas Oncology Hospital, BornovaRecruiting
  • Istanbul University-Cerrahpasa, Cerrahpasa Medical FacultyRecruiting
  • Goztepe Prof. Dr. Suleyman Yalcin Sehir HastanesiRecruiting
  • Guy's HospitalRecruiting
  • Christie Hospital NHS Trust
  • Christie Hospital NHS TrustRecruiting
  • Oxford University Hospitals NHS Foundation TrustRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

IO102-IO103 + pembrolizumab

pembrolizumab

Arm Description

IO102-IO103 subcutaneous injections (85µg) every 3 weeks for a maximum 35 cycles (up to 2 years treatment). Additional dose given during the induction period on Day 8 of cycles 1 and 2. Each patient can be treated for a maximum of 37 administrations in total (up to 2 years treatment). Pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles.

Pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles (up to 2 years treatment).

Outcomes

Primary Outcome Measures

Progression Free Survival (PFS)
PFS defined as the time from randomization to the first documented disease progression ((based on Independent Review Committee in accordance with RECIST v1.1) or death from any cause.

Secondary Outcome Measures

Overall Response Rate (ORR)
ORR defined as the percentage of patients achieving a confirmed PR or CR. ORR will be determined by an IRC in accordance with RECIST v1.1.
Overall survival (OS)
OS defined as the time from randomisation until death from any cause. months. This will be determined by an IRC in accordance with RECIST v1.1.
Durable Objective response rate (DRR)
DRR is defined as the percentage of patients achieving a PR or CR > 6 months. This will be determined by an IRC in accordance with RECIST v1.1.
Complete response rate (CRR)
Percentage of patients with a visit response of CR, which will be determined by the IRC in accordance with RECIST v1.1.
Duration of response (DoR)
DoR will be measured from the date of first observed objective response until disease progression or death (whichever is earlier) (based on IRC).
Time to response (TTR)
TTR is defined as the time from the date of randomization to the date of first observed PR or CR (based on IRC).
Time to complete response (TTCR)
TTCR is defined as the time from the date of randomization to the date of first observed CR (based on IRC).
Disease control rate (DCR)
DCR is defined as the percentage of patients achieving a PR or CR or SD (based on IRC).
Incidence of e.g. AEs and SAEs (Safety and Tolerability)
Incidence of AEs and SAEs, and treatment related AEs and SAEs. Incidence of AEs causing discontinuation of trial treatment.

Full Information

First Posted
November 30, 2021
Last Updated
September 11, 2023
Sponsor
IO Biotech
Collaborators
Syneos Health, Merck Sharp & Dohme LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT05155254
Brief Title
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Official Title
An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D18)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 17, 2022 (Actual)
Primary Completion Date
July 2025 (Anticipated)
Study Completion Date
September 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
IO Biotech
Collaborators
Syneos Health, Merck Sharp & Dohme LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Phase 3, multicenter, international, open-label, randomized, 2-arm trial investigating the safety and efficacy of IO102-IO103 in combination with pembrolizumab as first-line treatment for patients with previously untreated unresectable or metastatic (advanced) melanoma. Patients will be stratified on the basis of the following factors; Disease stage: Stage III (unresectable) and IV M1a-b versus stage IV M1c-d and BRAFV600 mutation status: mutated vs wild type. All patients will receive pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles (up to 2 years treatment). Patients randomized to IO102-IO103 dual-antigen, immunotherapeutic arm will also be given IO102-IO103 Q3W with an additional dose given during the induction period on Day 8 of cycles 1 and 2. IO102 IO103 will thereafter be administered subcutaneous every 3 weeks during the maintenance period. Each patient can be treated for a maximum of 37 administrations in total (up to 2 years of treatment). The primary objective is to investigate the efficacy of IO102-IO103 in combination with pembrolizumab (compared with pembrolizumab alone) in terms of progression free survival.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metastatic Melanoma, Unresectable Melanoma
Keywords
Metastatic melanoma, Unresectable melanoma, Immunotherapy, Progression free survival, IO102-IO103, Pembrolizumab

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Patients will be randomised 1:1 to receive either dual-antigen IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone
Masking
None (Open Label)
Allocation
Randomized
Enrollment
380 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
IO102-IO103 + pembrolizumab
Arm Type
Experimental
Arm Description
IO102-IO103 subcutaneous injections (85µg) every 3 weeks for a maximum 35 cycles (up to 2 years treatment). Additional dose given during the induction period on Day 8 of cycles 1 and 2. Each patient can be treated for a maximum of 37 administrations in total (up to 2 years treatment). Pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles.
Arm Title
pembrolizumab
Arm Type
Active Comparator
Arm Description
Pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles (up to 2 years treatment).
Intervention Type
Drug
Intervention Name(s)
IO102-IO103
Intervention Description
IO102-IO103 comprises IDO peptide antigen (IO102) and PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) administered subcutaneously
Intervention Type
Drug
Intervention Name(s)
Pembrolizumab
Intervention Description
Pembrolizumab administered intravenously
Primary Outcome Measure Information:
Title
Progression Free Survival (PFS)
Description
PFS defined as the time from randomization to the first documented disease progression ((based on Independent Review Committee in accordance with RECIST v1.1) or death from any cause.
Time Frame
Approximately 3.5 years
Secondary Outcome Measure Information:
Title
Overall Response Rate (ORR)
Description
ORR defined as the percentage of patients achieving a confirmed PR or CR. ORR will be determined by an IRC in accordance with RECIST v1.1.
Time Frame
Approximately 2.5 years
Title
Overall survival (OS)
Description
OS defined as the time from randomisation until death from any cause. months. This will be determined by an IRC in accordance with RECIST v1.1.
Time Frame
Approximately 5.5 years
Title
Durable Objective response rate (DRR)
Description
DRR is defined as the percentage of patients achieving a PR or CR > 6 months. This will be determined by an IRC in accordance with RECIST v1.1.
Time Frame
Approximately 3.5 years
Title
Complete response rate (CRR)
Description
Percentage of patients with a visit response of CR, which will be determined by the IRC in accordance with RECIST v1.1.
Time Frame
Approximately 3.5 years
Title
Duration of response (DoR)
Description
DoR will be measured from the date of first observed objective response until disease progression or death (whichever is earlier) (based on IRC).
Time Frame
Approximately 3.5 years
Title
Time to response (TTR)
Description
TTR is defined as the time from the date of randomization to the date of first observed PR or CR (based on IRC).
Time Frame
Approximately 3.5 years
Title
Time to complete response (TTCR)
Description
TTCR is defined as the time from the date of randomization to the date of first observed CR (based on IRC).
Time Frame
Approximately 3.5 years
Title
Disease control rate (DCR)
Description
DCR is defined as the percentage of patients achieving a PR or CR or SD (based on IRC).
Time Frame
Approximately 3.5 years
Title
Incidence of e.g. AEs and SAEs (Safety and Tolerability)
Description
Incidence of AEs and SAEs, and treatment related AEs and SAEs. Incidence of AEs causing discontinuation of trial treatment.
Time Frame
Approximately 3.5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically or cytologically confirmed stage III (unresectable) or stage IV melanoma, as per American Joint Committee on Cancer 8th edition guidelines not amenable to local therapy Patients are treatment naive, that is, no previous systemic anticancer therapy for unresectable or metastatic melanoma. For clarification, the following patients are eligible: Patients with BRAFV600 mutation-positive melanoma are eligible if treatment naive and without rapidly progressive disease as per investigators assessment. Documented BRAF V600 mutation status must be available from all patients prior to trial entry. Patients who have received previous adjuvant and/or neoadjuvant therapy with targeted therapy or immune therapy are eligible if administered the last dose at least 6 months before inclusion in this trial (randomization), and if relapse did not occur during active treatment or within 6 months of treatment discontinuation. At least 1 measurable lesion according to response evaluation criteria for solid tumors (RECIST v1.1) and confirmed by IRC. Provision of archival (obtained within 3 months), or newly acquired biopsy tissue not previously irradiated, and blood at screening for biomarker assessments. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue. Exclusion Criteria: Patients with known or suspected central nervous system (CNS) metastases or with the CNS as the only site of active disease are excluded with the following exception: • Patients with controlled (stable) brain metastases will be allowed to enroll (subject to baseline magnetic resonance imaging (MRI) confirmation). Controlled (stable) brain metastases are defined as those with no radiographic progression for at least 4 weeks after radiation and/or surgical treatment at the time of signed informed consent. Patients must have been off steroids for at least 2 weeks before signed informed consent and have no new or progressive neurological signs and symptoms. Patient has received previous radiotherapy within 2 weeks of start of trial treatment (visit 2). Patients must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease. Patients with BRAFV600-positive disease who are experiencing rapidly progressing disease and/or have received standard first-line therapy with BRAF and/or MEK inhibitor for unresectable or metastatic disease. Other protocol defined inclusion/exclusion criteria may apply.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Francois Philippe Ringeisen VP of Clinical Development, MD, PhD
Phone
+41782396763
Email
fpr@iobiotech.com
First Name & Middle Initial & Last Name or Official Title & Degree
Anita Vedel Senior Director Clinical Operations, MSc Pharm
Phone
+45 31 10 97 91
Email
av@iobiotech.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Inge Marie Svane, MD, Prof
Organizational Affiliation
Institut for Klinisk Medicin, Herlev-Gentofte Hospital; Denmark
Official's Role
Principal Investigator
Facility Information:
Facility Name
Providence Saint John's Health Center
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Individual Site Status
Withdrawn
Facility Name
Mid Florida Hematology and Oncology Center
City
Orange City
State/Province
Florida
ZIP/Postal Code
32763
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Santosh Nair
Email
drsmnair@aorcorp.com
First Name & Middle Initial & Last Name & Degree
Santosh Nair, MD
Facility Name
Orlando Health Cancer Institute
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sajeve Thomas, MD
Email
sajeve.thomas@orlandohealth.com
First Name & Middle Initial & Last Name & Degree
Sajeve Thomas, MD
Facility Name
University of Kentucky Markey Cancer Center
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40536
Country
United States
Individual Site Status
Withdrawn
Facility Name
Roswell Park Cancer Institute
City
Buffalo
State/Province
New York
ZIP/Postal Code
14221
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Igor Puzanov, M.D.
Email
Igor.Puzanov@RoswellPark.org
First Name & Middle Initial & Last Name & Degree
Igor Puzanov, M.D.
Facility Name
VCU Massey Cancer Center
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23219
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrew Poklepovic
Email
andrew.poklepovic@vcuhealth.org
First Name & Middle Initial & Last Name & Degree
Andrew Poklepovic
Facility Name
Border Medical Oncology Research Unit
City
Albury
State/Province
New South Wales
ZIP/Postal Code
2640
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Craig Underhill, M.D.
Email
Craig.Underhill@bordermedonc.com.au
First Name & Middle Initial & Last Name & Degree
Craig Underhill, M.D.
Facility Name
Westmead Hospital
City
Westmead
State/Province
New South Wales
ZIP/Postal Code
2145
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matteo Carlino, M.D.
Email
matteo.carlino@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Matteo Carlino, M.D.
Facility Name
Southern Medical Day Care Centre
City
Wollongong
State/Province
New South Wales
ZIP/Postal Code
2500
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Brungs, M.D./Prof.
Email
Daniel.Brungs@health.nsw.gov.au
First Name & Middle Initial & Last Name & Degree
Daniel Brungs, M.D. A/Prof.
Facility Name
Cairns Hospital
City
Cairns
State/Province
Queensland
ZIP/Postal Code
4870
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Megan Lyle, M.D.
Email
Megan.Lyle@health.qld.gov.au
First Name & Middle Initial & Last Name & Degree
Megan Lyle, M.D.
Facility Name
Flinders Medical Centre
City
Bedford Park
State/Province
South Australia
ZIP/Postal Code
5042
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amitesh Roy
Email
Amitesh.Roy@sa.gov.au
First Name & Middle Initial & Last Name & Degree
Amitesh Roy
Facility Name
The Queen Elizabeth Hospital
City
Woodville South
State/Province
South Australia
ZIP/Postal Code
5011
Country
Australia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rachel Roberts-Thomson, MD
Email
rachel.roberts-thomson@sa.gov.au
First Name & Middle Initial & Last Name & Degree
Rachel Roberts-Thomson, MD
Facility Name
Sunshine Coast University Hospital
City
Birtinya
ZIP/Postal Code
4575
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mary Azer, M.D.
Email
Mary.Azer@health.qld.gov.au
First Name & Middle Initial & Last Name & Degree
Mary Azer, M.D.
Facility Name
Peter MacCallum Cancer Centre PMCC - East Melbourne
City
Melbourne
ZIP/Postal Code
3052
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shahneen Sandhu, M.D.
Email
shahneen.sandhu@petermac.org
First Name & Middle Initial & Last Name & Degree
Shahneen Sandhu, M.D.
Facility Name
Universitair Ziekenhuis Gent UZ Gent
City
Gent
State/Province
Oost-Vlaanderen
ZIP/Postal Code
9000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Celine Jacobs, M.D.
Email
celine.jacobs@uzgent.be
First Name & Middle Initial & Last Name & Degree
Celine Jacobs, M.D.
Facility Name
AZ Sint-Jan Brugge - Oostende AV - Campus Sint-Jan
City
Brugge
ZIP/Postal Code
8000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alain Bols, MD
Email
alain.bols@azsintjan.be
First Name & Middle Initial & Last Name & Degree
Alain Bols, MD
Facility Name
CHIREC
City
Brussels
ZIP/Postal Code
1160
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Corinne Gregoire
Email
md.corinne.gregoire@gmail.com
First Name & Middle Initial & Last Name & Degree
Corinne Gregoire
Facility Name
AZ Nikolaas
City
Sint-Niklaas
ZIP/Postal Code
9100
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vibeke Kruse, MD
Email
Vibeke.Kruse@vitaz.be
First Name & Middle Initial & Last Name & Degree
Vibeke Kruse, MD
Facility Name
FNHK Klinika onkologie a radioterapie
City
Hradec Králové
ZIP/Postal Code
500 05
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jindrich Kopecky, MD
Email
jindrich.kopecky@fnhk.cz
First Name & Middle Initial & Last Name & Degree
Jindrich Kopecky, MD
Facility Name
Fakultni Nemocnice Olomouc
City
Olomouc
ZIP/Postal Code
779 00
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bohuslav Melichar, MD
Email
bohuslav.melichar@fnol.cz
First Name & Middle Initial & Last Name & Degree
Bohuslav Melichar, MD
Facility Name
FN Ostrava
City
Ostrava
ZIP/Postal Code
708 52
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yvetta Vantuchova, MD
Email
yvetta.vantuchova@fno.cz
First Name & Middle Initial & Last Name & Degree
Yvetta Vantuchova, MD
Facility Name
FNKV Department of Dermatology
City
Praha
ZIP/Postal Code
10034
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Monika Arenbergerova, MD
Email
arenbergerova@email.cz
First Name & Middle Initial & Last Name & Degree
Monika Arenbergerova, MD
Facility Name
Aalborg University Hospital
City
Aalborg
ZIP/Postal Code
9000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Charlotte Haslund, MD
Email
cah@rn.dk
First Name & Middle Initial & Last Name & Degree
Charlotte Haslund, MD
Facility Name
Aarhus University Hospital
City
Aarhus
ZIP/Postal Code
8200
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Henrik Schmidt, MD
Email
henrschm@rm.dk
First Name & Middle Initial & Last Name & Degree
Henrik Schmidt, MD
Facility Name
Herlev og Gentofte Hospital
City
Herlev
ZIP/Postal Code
2730
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Inge M. Svane, M.D.
Email
inge.marie.svane@regionh.dk
First Name & Middle Initial & Last Name & Degree
Inge M. Svane, M.D.
Facility Name
Odense University Hospital
City
Odense
ZIP/Postal Code
5000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lars Bastholt
Email
lars.bastholt@rsyd.dk
First Name & Middle Initial & Last Name & Degree
Lars Bastholt
Facility Name
Centre Hospitalier Universitaire de Besançon Jean Minjoz
City
Besancon
ZIP/Postal Code
25000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Charlee Nardin, Dr.
First Name & Middle Initial & Last Name & Degree
Charlee Nardin, Dr.
Facility Name
Centre Hospitalier Universitaire de Bordeaux Hospital Saint Andre
City
Bordeaux
ZIP/Postal Code
33075
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Caroline Dutriaux, M.D.
Email
caroline.dutriaux@chu-bordeaux.fr
First Name & Middle Initial & Last Name & Degree
Caroline Dutriaux, M.D.
Facility Name
Hopital Ambroise
City
Boulogne Billancourt
ZIP/Postal Code
92100
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Philippe Saiag, Prof.
First Name & Middle Initial & Last Name & Degree
Philippe Saiag, Prof
Facility Name
Centre Georges Francois Leclerc
City
Dijon
ZIP/Postal Code
21079
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alice Hervieu, MD
Email
ahervieu@cgfl.fr
First Name & Middle Initial & Last Name & Degree
Alice Hervieu, MD
Facility Name
Chu Grenoble - Hopital Albert Michallon
City
La Tronche
ZIP/Postal Code
38700
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marie Enquebecq, MD
Email
menquebecq@chu-grenoble.fr
First Name & Middle Initial & Last Name & Degree
Marie Enquebecq, MD
Facility Name
Centre Hospitalier Universitaire de Lille
City
Lille
ZIP/Postal Code
59000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laurent Mortier, M.D.
Email
Laurent.MORTIER@CHRU-LILLE.FR
First Name & Middle Initial & Last Name & Degree
Laurent Mortier, M.D.
Facility Name
Hôpital de La Timone
City
Marseille cedex 05
ZIP/Postal Code
13385
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Caroline Gaudy, Prof
Email
caroline.gaudy@ap-hm.fr
First Name & Middle Initial & Last Name & Degree
Caroline Gaudy, Prof
Facility Name
CHU de Nice Hpital de lArchet 2
City
Nice
ZIP/Postal Code
6200
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Henri Montaudie, MD
Email
montaudie.h@chu-nice.fr
First Name & Middle Initial & Last Name & Degree
Henri Montaudie, MD
Facility Name
Centre Hospitalier Lyon Sud
City
Pierre Benite
ZIP/Postal Code
69495
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephane Dalle, M.D.
Phone
478861679
Email
stephane.dalle@chu-lyon.fr
First Name & Middle Initial & Last Name & Degree
Stephane Dalle, M.D.
Facility Name
Centre Eugene Marquis
City
Rennes Cedex
ZIP/Postal Code
35042
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thierry Lesimple, M.D.
Email
t.lesimple@rennes.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Thierry Lesimple, M.D.
Facility Name
Institut de Cancérologie de L'Ouest
City
Saint Herblain
ZIP/Postal Code
44805
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Melanie Saint-Jean
Email
Melanie.SaintJean@ico.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Melanie Saint-Jean, MD
Facility Name
Centre Hospitalier de Valence (CHV)
City
Valence
ZIP/Postal Code
26 953
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Florent Grange, M.D.
Email
fgrange@ch-valence.fr
First Name & Middle Initial & Last Name & Degree
Florent Grange, M.D.
Facility Name
Gustave Roussy
City
Villejuif Cedex
ZIP/Postal Code
94805
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Caroline Robert, M.D.
Email
Caroline.ROBERT@gustaveroussy.fr
First Name & Middle Initial & Last Name & Degree
Caroline Robert, M.D.
Facility Name
Universitatsklinikum Augsburg Medizincampus Sued
City
Augsburg
ZIP/Postal Code
86179
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Julia Welzel, MD
Email
Julia.welzel@uk-augsburg.de
First Name & Middle Initial & Last Name & Degree
Julia Welzel, MD
Facility Name
Charite Universitaetsmedizin Berlin
City
Berlin
ZIP/Postal Code
13353
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Max Schlaak, M.D.
Email
max.schlaak@charite.de
First Name & Middle Initial & Last Name & Degree
Max Schlaak, M.D.
Facility Name
St. Josef Hospital - Ruhr-Universitt Bochum
City
Bochum
ZIP/Postal Code
44791
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thilo Gamblichler
Email
t.gambichler@klinikum-bochum.de
First Name & Middle Initial & Last Name & Degree
Thilo Gamblicher
Facility Name
University Hospital Erlangen
City
Erlangen
ZIP/Postal Code
90054
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carola Berking, MD
Email
carola.berking@uk-erlangen.de
First Name & Middle Initial & Last Name & Degree
Carola Berking, MD
Facility Name
Universitaetsklinikum Essen
City
Essen
ZIP/Postal Code
45147
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dirk Schadendorf, M.D.
Phone
2017232325
Email
dirk.schadendorf@uk-essen.de
First Name & Middle Initial & Last Name & Degree
Dirk Schadendorf, M.D.
Facility Name
University Hospital Frankfurt Theodor-Stern-Kai
City
Frankfurt
ZIP/Postal Code
60590
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Roland Kaufmann, MD
Email
kaufmann.klifo@kgu.de
First Name & Middle Initial & Last Name & Degree
Roland Kaufmann, MD
Facility Name
Elbe Klinikum Buxtehude
City
Hamburg
ZIP/Postal Code
22045
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter Mohr
Email
peter.mohr@elbekliniken.de
First Name & Middle Initial & Last Name & Degree
Peter Mohr
Facility Name
Nationales Centrum fr Tumorerkrankungen NCT
City
Heidelberg
ZIP/Postal Code
69120
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jessica Hassel, M.D.
Phone
6221568562
Email
Jessica.Hassel@med.uni-heidelberg.de
First Name & Middle Initial & Last Name & Degree
Jessica Hassel, M.D.
Facility Name
SLK-Kliniken Heilbronn GmbH
City
Heilbronn
ZIP/Postal Code
74078
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Uwe Martens, M.D.
Email
uwe.martens@slk-kliniken.de
First Name & Middle Initial & Last Name & Degree
Uwe Martens, M.D.
Facility Name
Universitaetsklinikum Schleswig-Holstein
City
Kiel
ZIP/Postal Code
24105
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patrick Terheyden, MD
Email
Patrick.Terheyden@uksh.de
First Name & Middle Initial & Last Name & Degree
Patrick Terheyden, MD
Facility Name
Department of Dermatology University of Mainz
City
Mainz
ZIP/Postal Code
55131
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephan Grabbe, MD
Email
stephan.grabbe@unimedizin-mainz.de
First Name & Middle Initial & Last Name & Degree
Stephan Grabbe, MD
Facility Name
Universitatsmedizin Mannheim Dermatologie
City
Mannheim
ZIP/Postal Code
68167
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jochen Utikal, MD
Email
jochen.utikal@umm.de
First Name & Middle Initial & Last Name & Degree
Jochen Utikal, MD
Facility Name
Mühlenkreiskliniken AöR, University Hospital Ruhr University Bochum Campus Minden
City
Minden
ZIP/Postal Code
32429
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ralf Gutzmer, Prof.
First Name & Middle Initial & Last Name & Degree
Ralf Gutzmer, Prof.
Facility Name
LMU Muenchen
City
Muenchen
ZIP/Postal Code
80337
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lucie Heinzerling, MD
Email
lucie.heinzerling@med.uni-muenchen.de
First Name & Middle Initial & Last Name & Degree
Lucie Heinzerling, MD
Facility Name
Hospital Tubingen
City
Tubingen
ZIP/Postal Code
72076
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Teresa Amaral, MD
Email
teresa.amaral@med.uni-tuebingen.de
First Name & Middle Initial & Last Name & Degree
Teresa Amaral, MD
Facility Name
Universittsklinikum Wuerzburg
City
Wuerzburg
ZIP/Postal Code
97080
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bastian Schilling, MD
Email
schilling_b@ukw.de
First Name & Middle Initial & Last Name & Degree
Bastian Schilling, MD
Facility Name
Orszagos Onkologiai Intezet
City
Budapest
ZIP/Postal Code
1122
Country
Hungary
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gabriella Liszkay, M.D.
Email
liszkay@oncol.hu
First Name & Middle Initial & Last Name & Degree
Gabriella Liszkay, M.D.
Facility Name
Bor, -Nemikortani es Onkodermatologiai Klinika
City
Pecs
ZIP/Postal Code
7632
Country
Hungary
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rolland Gyulai, M.D.
Email
gyulai.rolland@pte.hu
First Name & Middle Initial & Last Name & Degree
Rolland Gyulai, M.D.
Facility Name
Hetenyi G Korhaz, Onkologiai Kozpont
City
Szolnok
ZIP/Postal Code
5000
Country
Hungary
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tibor Csoszi, M.D.
Email
dr.cstibor@freemail.hu
First Name & Middle Initial & Last Name & Degree
Tibor Csoszi, M.D.
Facility Name
Mater Public Hospital
City
Dublin
ZIP/Postal Code
7
Country
Ireland
Individual Site Status
Withdrawn
Facility Name
Emek Medical Center
City
Afula
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gil Bar-Sela, MD
Email
gil_ba@clalit.org.il
First Name & Middle Initial & Last Name & Degree
Gil Bar-Sela, MD
Facility Name
Ben-Gurion University of the Negev - Soroka University Medical Center - Soroka Clinical Research Center
City
Beer Sheva
ZIP/Postal Code
84101
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexander Yakobson, MD
Email
Alexy@clalit.org.il
First Name & Middle Initial & Last Name & Degree
Alexander Yakobson, MD
Facility Name
Hadassah University Hospital
City
Jerusalem
ZIP/Postal Code
91120
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michal Lotem, MD
Email
mlotem@hadassah.org.il
First Name & Middle Initial & Last Name & Degree
Michal Lotem, MD
Facility Name
Rabin Medical Center
City
Petah Tikva
ZIP/Postal Code
4941492
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Hendler, MD
Email
Danielh@clalit.org.il
First Name & Middle Initial & Last Name & Degree
Daniel Hendler, MD
Facility Name
Tel Aviv Sourasky Medical Center
City
Tel Aviv-Yafo
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mor Miodovnik, MD
Email
mormio@gmail.com
First Name & Middle Initial & Last Name & Degree
Mor Miodovnik, MD
Facility Name
The Chaim Sheba Medical Center - The Ella Lemelbaum Institute for Immuno-Oncology
City
Tel Hashomer
ZIP/Postal Code
5262100
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ronnie Shapira-Frommer, MD
Email
ronnie.shapira@sheba.health.gov.il
First Name & Middle Initial & Last Name & Degree
Ronnie Shapira-Frommer, MD
Facility Name
Clinica Oncologica, AOU Riuniti ancona
City
Ancona
ZIP/Postal Code
60126
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rossana Berardi, MD
Email
rossana.berardi@ospedaliriuniti.marche.it
First Name & Middle Initial & Last Name & Degree
Rossana Berardi
Facility Name
Centro di Riferimento Oncologico
City
Aviano
ZIP/Postal Code
33081
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Silvia Bolzonello, MD
Email
silvia.bolzonello@cro.it
First Name & Middle Initial & Last Name & Degree
Silvia Bolzonello, MD
Facility Name
Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari
City
Bari
ZIP/Postal Code
70124
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michele Guida, MD
Email
micguida57@gmail.com
First Name & Middle Initial & Last Name & Degree
Michele Guida, MD
Facility Name
IRCCS Ospedale San Raffaele
City
Candiolo
ZIP/Postal Code
10060
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vanesa Gregorc, MD
Email
vanesa.gregorc@ircc.it
First Name & Middle Initial & Last Name & Degree
Vanesa Gregorc, MD
Facility Name
IRCCS Ospedale Policlinico San Martino
City
Genova
ZIP/Postal Code
16132
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francesco Spagnolo, MD
Email
francesco.spagnolo85@gmail.com
First Name & Middle Initial & Last Name & Degree
Francesco Spagnolo, MD
Facility Name
Istituto Romagnolo per lo Studio dei Tumori " DINO AMADORI"
City
Meldola
ZIP/Postal Code
47014
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Massimo Guidoboni, MD
Email
massimo.guidoboni@irst.emr.it
First Name & Middle Initial & Last Name & Degree
Massimo Guidoboni, MD
Facility Name
Fondazione IRCCS Istituto Nazionale dei Tumori
City
Milano
ZIP/Postal Code
20133
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michele Del Vecchio, MD
Email
michele.delvecchio@istitutotumori.mi.it
First Name & Middle Initial & Last Name & Degree
Michele Del Vecchio, MD
Facility Name
Istituto Nazionale Tumori IRCCS Fondazione Pascale
City
Napoli
ZIP/Postal Code
80131
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paolo Ascierto, MD
Email
paolo.ascierto@gmail.com
First Name & Middle Initial & Last Name & Degree
Paolo Ascierto, MD
Facility Name
Veneto Oncology Institute
City
Padova
ZIP/Postal Code
35128
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vanna C. Sileni, MD
Email
vanna.chiarion@iov.veneto.it
First Name & Middle Initial & Last Name & Degree
Vanna C. Sileni, MD
Facility Name
Ospedale S. Maria della Misericordia
City
Perugia
ZIP/Postal Code
6156
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mario Mandala, Prof
Email
mario.mandala@unipg.it
First Name & Middle Initial & Last Name & Degree
Mario Mandalá
Facility Name
Idi-Irccs
City
Rome
ZIP/Postal Code
00167
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paolo Marchetti, MD
Email
paolo.marchetti@uniroma1.it
First Name & Middle Initial & Last Name & Degree
Paolo Marchetti, MD
Facility Name
Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte
City
Siena
ZIP/Postal Code
53100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michele Maio, Prof
Email
mmaiocro@gmail.com
First Name & Middle Initial & Last Name & Degree
MIchele Maio, Prof
Facility Name
The Netherlands Cancer Institute
City
Amsterdam
ZIP/Postal Code
1066
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Blank, M.D.
Email
c.blank@nki.nl
First Name & Middle Initial & Last Name & Degree
Christian Blank, M.D.
Facility Name
AMC Amsterdam, locatie VUMC
City
Amsterdam
ZIP/Postal Code
1081
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fons van den Eertwegh, MD
Email
vandeneertwegh@amsterdamumc.nl
First Name & Middle Initial & Last Name & Degree
Fons van den Eertwegh, MD
Facility Name
LUMC
City
Leiden
ZIP/Postal Code
2300 RC
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ellen Kapiteijn, MD
Email
h.w.kapiteijn@lumc.nl
First Name & Middle Initial & Last Name & Degree
Ellen Kapiteijn, MD
Facility Name
UMC Maastricht
City
Maastricht
ZIP/Postal Code
6229HX
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maureen Aarts, MD
Email
mjb.essers.aarts@mumc.nl
First Name & Middle Initial & Last Name & Degree
Maureen Aarts, MD
Facility Name
Erasmus MC
City
Rotterdam
ZIP/Postal Code
1054 ZG
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Astrid van der Veldt, MD
Email
a.vanderveldt@erasmusmc.nl
First Name & Middle Initial & Last Name & Degree
Astrid van der Veldt, MD
Facility Name
University Medical Center Utrecht
City
Utrecht
ZIP/Postal Code
3584
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karijn Suijkerbuijk, MD
Email
K.Suijkerbuijk@umcutrecht.nl
First Name & Middle Initial & Last Name & Degree
Karijn Suijkerbuijk, MD
Facility Name
Maria Sklodowska-Curie National Research Institute of Oncology
City
Warsaw
State/Province
Masovian
ZIP/Postal Code
02-781
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Piotr Rutkowski
Email
piotr.rutkowski@pib-nio.pl
First Name & Middle Initial & Last Name & Degree
Piotr Rutkowski
Facility Name
Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu
City
Poznan
ZIP/Postal Code
60-780
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jacek Mackiewicz, MD
Email
jmackiewicz@ump.edu.pl
First Name & Middle Initial & Last Name & Degree
Jacek Mackiewicz, MD
Facility Name
Cape Town Oncology Trials (Pty) Ltd.
City
Cape Town
ZIP/Postal Code
7570
Country
South Africa
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Conrad Jacobs, M.D.
Email
conrad.jacobs@cancercare.co.za
First Name & Middle Initial & Last Name & Degree
Conrad Jacobs, M.D.
Facility Name
Mary Potter Oncology Centre Groenkloof
City
Pretoria
ZIP/Postal Code
0181
Country
South Africa
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cohen Graham, MD
Email
glcresearch@mpoc.co.za
First Name & Middle Initial & Last Name & Degree
Cohen Graham, MD
Facility Name
Hospital Universitario Virgen Macarena
City
Seville
State/Province
Andalusia
ZIP/Postal Code
41009
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luis de la Cruz Merino, M.D.
Email
ldelacruzmerino@gmail.com
First Name & Middle Initial & Last Name & Degree
Luis de la Cruz Merino, M.D.
Facility Name
CH Universitario de A Coruña (CHUAC)
City
A Coruña
ZIP/Postal Code
15006
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Q. Varela, M.D.
Email
maria.quindos.varela@sergas.es
First Name & Middle Initial & Last Name & Degree
Maria Q. Varela, M.D.
Facility Name
Hospital Clinic i Provincial
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ana Maria A Fernandez, M.D.
Email
amarance@clinic.cat
First Name & Middle Initial & Last Name & Degree
Ana Maria A Fernandez, M.D.
Facility Name
Instituto Oncologico Dr. Rosell IOR - Hospital Universitari Quiron Dexeus
City
Barcelona
ZIP/Postal Code
8028
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Gonzalez-Cao, M.D.
Email
mgonzalezcao@oncorosell.com
First Name & Middle Initial & Last Name & Degree
Maria Gonzalez-Cao, M.D.
Facility Name
Hospital Universitari Germans Trias i Pujol HUGTP, ICO-Badalona
City
Barcelona
ZIP/Postal Code
8916
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jose Luis M. Mozo, MD
Email
jmanzano@iconcologia.net
First Name & Middle Initial & Last Name & Degree
Jose Luis M Mozo, MD
Facility Name
Hospital Vall d'hebron
City
Barcelona
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eva Munoz Cosuelo
Email
emunoz@vhio.net
First Name & Middle Initial & Last Name & Degree
Eva Munoz Cosuelo
Facility Name
Hospital General Universitario Gregorio Marañon
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ivan Marquez Rodas, MD
Email
ivanpantic@hotmail.com
First Name & Middle Initial & Last Name & Degree
Ivan Marquez Rodas, MD
Facility Name
Clinica Universidad de Navarra
City
Madrid
ZIP/Postal Code
28027
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
EDUARDO CASTAÑON, MD
Email
ecastanon@unav.es
First Name & Middle Initial & Last Name & Degree
EDUARDO CASTAÑON, MD
Facility Name
Hospital Universitario Ramon y Cajal
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ainara S. Rivas, M.D.
Email
ainarasoria@hotmail.com
First Name & Middle Initial & Last Name & Degree
Ainara S Rivas, M.D.
Facility Name
Hospital Universitario HM Sanchinarro
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Juan Francisco Rodriguez, M.D.
Email
jfrodriguez@hmhospitales.com
First Name & Middle Initial & Last Name & Degree
Juan Francisco Rodriguez, M.D.
Facility Name
Hospital Regional Universitario de Malaga
City
Malaga
ZIP/Postal Code
29010
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Miguel Berciano, MD
Email
migueberci@gmail.com
First Name & Middle Initial & Last Name & Degree
Miguel Berciano, MD
Facility Name
Hospital Universitario Central de Asturias (HUCA)
City
Oviedo
ZIP/Postal Code
33011
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Isabel Palacio Vazquez, MD
Email
isabel.palacio@sespa.es
First Name & Middle Initial & Last Name & Degree
Isabel Palacio Vazquez, MD
Facility Name
Clinica Universidad de Navarra
City
Pamplona
ZIP/Postal Code
31008
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eduardo C. Alvarez, MD
Email
ecastanon@unav.es
First Name & Middle Initial & Last Name & Degree
Eduardo C. Alvarez, MD
Facility Name
Hospital General Universitario de Valencia
City
Valencia
ZIP/Postal Code
46014
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alfonso Berrocal Jaime, MD
Email
berrocal.alf@gmail.com
First Name & Middle Initial & Last Name & Degree
Alfonso Berrocal Jaime, MD
Facility Name
Hospital Universitari i Politecnic La Fe
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Roberto D. Beveridge, M.D.
Email
diaz_rob@gva.es
First Name & Middle Initial & Last Name & Degree
Roberto D. Beveridge, M.D.
Facility Name
Miguel Servet University Hospital
City
Zaragoza
ZIP/Postal Code
50009
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Teresa Puertolas Hernandez, MD
Email
tjpuertolas@gmail.com
First Name & Middle Initial & Last Name & Degree
Teresa Puertolas Hernandez, MD
Facility Name
Adana City Education and Research Hospital
City
Adana
ZIP/Postal Code
1060
Country
Turkey
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cil Timucin, MD
Email
drtimucincil@gmail.com
First Name & Middle Initial & Last Name & Degree
Cil Timucin, MD
Facility Name
Gulhane School of Medicine
City
Ankara
ZIP/Postal Code
6010
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nuri Karadurmus, MD
Email
drnkaradurmus@yahoo.com
First Name & Middle Initial & Last Name & Degree
Nuri Karadurmus, MD
Facility Name
Memorial Ankara Hospital
City
Ankara
ZIP/Postal Code
6520
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Umut Demirci, MD
Email
drumutdemirci@gmail.com
First Name & Middle Initial & Last Name & Degree
Umut Demirci, MD
Facility Name
Akdeniz University Medical Faculty
City
Antalya
ZIP/Postal Code
7059
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sema S. Goksu, MD
Email
semasezgingoksu@gmail.com
First Name & Middle Initial & Last Name & Degree
Sema S. Goksu, MD
Facility Name
Ege university Faculty of Medicine, T. Aktas Oncology Hospital, Bornova
City
Bornova
ZIP/Postal Code
35100
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Saziye B Karaca, MD
Email
karacaburcak@hotmail.com
First Name & Middle Initial & Last Name & Degree
Saziye B Karaca
Facility Name
Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty
City
Istanbul
ZIP/Postal Code
34098
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mustafa Ozguroglu, MD
Email
ozguroglu@gmail.com
First Name & Middle Initial & Last Name & Degree
Mustafa Ozguroglu
Facility Name
Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
City
Istanbul
ZIP/Postal Code
34722
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mahmut Gumus, MD
Email
mgumus@superonline.com
First Name & Middle Initial & Last Name & Degree
Mahmut Gumus, MD
Facility Name
Guy's Hospital
City
London
ZIP/Postal Code
SE1 9RT
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yin Wu, MD
Email
yin.wu@kcl.ac.uk
First Name & Middle Initial & Last Name & Degree
Yin Wu, MD
Facility Name
Christie Hospital NHS Trust
City
Manchester
ZIP/Postal Code
M20 4BX
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paul Lorigan, MD
Email
paul.lorigan@nhs.net
First Name & Middle Initial & Last Name & Degree
Paul Lorigan, MD
Facility Name
Christie Hospital NHS Trust
City
Manchester
ZIP/Postal Code
M20 4XB
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Avinash Gupta, MD
Email
Avinash.gupta@nhs.net
First Name & Middle Initial & Last Name & Degree
Avinash Gupta, Dr
Facility Name
Oxford University Hospitals NHS Foundation Trust
City
Oxford
ZIP/Postal Code
OX3 7LE
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Miranda Payne, Dr
Email
miranda.payne@ouh.nhs.uk
First Name & Middle Initial & Last Name & Degree
Miranda Payne, Dr

12. IPD Sharing Statement

Learn more about this trial

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

We'll reach out to this number within 24 hrs